AbCellera Biologics
ABCL
138 hedge funds and large institutions have $434M invested in AbCellera Biologics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 34 reducing their positions, and 26 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 34
17% more capital invested
Capital invested by funds: $371M → $434M (+$63.4M)
4.78% more ownership
Funds ownership: 36.22% → 40.99% (+4.8%)
4% less funds holding
Funds holding: 144 → 138 (-6)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
33% less call options, than puts
Call options by funds: $9.08M | Put options by funds: $13.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$34.3M |
| 2 |
Two Sigma Investments
New York
|
+$17.1M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$9.9M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$9.88M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.16M |
| 2 |
Morgan Stanley
New York
|
-$2.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.79M |
| 4 |
Goldman Sachs
New York
|
-$2.13M |
| 5 |
Jane Street
New York
|
-$1.98M |
ABCL Hedge Fund Activity: Q1 2026 in Review
138 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2026, worth a combined $434M — up 17% from $371M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ABCL and 20 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 54 added.
The largest buyer was TD Waterhouse Canada, adding an estimated $34.3M. The largest seller was Renaissance Technologies, cutting an estimated $3.16M.
- 138 institutional investors held AbCellera Biologics (ABCL) as of Q1 2026, down from 144 in Q4 2025.
- Funds reported $434M of AbCellera Biologics stock for Q1 2026, up 17% quarter-over-quarter.
- 20 funds opened new AbCellera Biologics positions in Q1 2026 and 26 closed out, a net change of -6 holders.
- The largest AbCellera Biologics buyer in Q1 2026 was TD Waterhouse Canada, an estimated $34.3M added.
- The largest AbCellera Biologics seller in Q1 2026 was Renaissance Technologies, an estimated $3.16M sold.
Based on aggregated 13F filings for Q1 2026.